Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
J P Clancy, L Dupont, M W Konstan, J Billings, S Fustik, C H Goss, J Lymp, P Minic, A L Quittner, R C Rubenstein, K R Young, L Saiman, J L Burns, J R W Govan, B Ramsey, R Gupta, Arikace Study Group, J Clancy, R Young, R Ahrens, M Aitken, J Billings, A Faro, C Goss, D Layish, N Lechtzin, M Light, S Miller, S Nasr, J Nick, Rc Rubenstein, A Sannuti, G Sawicki, J Taylor-Cousar, B Trapnell, J Wallace, P Minic, S Fustik, E Solyom, H Mazurek, Y Antipkin, A Feketeova, A Senatorova, E Csiszer, V Kostromina, B Takac, R Ujhelyi, A Sovtic, Anne Marie Buccat, Catherine Doherty, J P Clancy, L Dupont, M W Konstan, J Billings, S Fustik, C H Goss, J Lymp, P Minic, A L Quittner, R C Rubenstein, K R Young, L Saiman, J L Burns, J R W Govan, B Ramsey, R Gupta, Arikace Study Group, J Clancy, R Young, R Ahrens, M Aitken, J Billings, A Faro, C Goss, D Layish, N Lechtzin, M Light, S Miller, S Nasr, J Nick, Rc Rubenstein, A Sannuti, G Sawicki, J Taylor-Cousar, B Trapnell, J Wallace, P Minic, S Fustik, E Solyom, H Mazurek, Y Antipkin, A Feketeova, A Senatorova, E Csiszer, V Kostromina, B Takac, R Ujhelyi, A Sovtic, Anne Marie Buccat, Catherine Doherty
Abstract
Rationale: Arikace is a liposomal amikacin preparation for aerosol delivery with potent Pseudomonas aeruginosa killing and prolonged lung deposition.
Objectives: To examine the safety and efficacy of 28 days of once-daily Arikace in cystic fibrosis (CF) patients chronically infected with P aeruginosa.
Methods: 105 subjects were evaluated in double-blind, placebo-controlled studies. Subjects were randomised to once-daily Arikace (70, 140, 280 and 560 mg; n=7, 5, 21 and 36 subjects) or placebo (n=36) for 28 days. Primary outcomes included safety and tolerability. Secondary outcomes included lung function (forced expiratory volume at one second (FEV1)), P aeruginosa density in sputum, and the Cystic Fibrosis Quality of Life Questionnaire-Revised (CFQ-R).
Results: The adverse event profile was similar among Arikace and placebo subjects. The relative change in FEV1 was higher in the 560 mg dose group at day 28 (p=0.033) and at day 56 (28 days post-treatment, 0.093L±0.203 vs -0.032L±0.119; p=0.003) versus placebo. Sputum P aeruginosa density decreased >1 log in the 560 mg group versus placebo (days 14, 28 and 35; p=0.021). The Respiratory Domain of the CFQ-R increased by the Minimal Clinically Important Difference (MCID) in 67% of Arikace subjects (560 mg) versus 36% of placebo (p=0.006), and correlated with FEV1 improvements at days 14, 28 and 42 (p<0.05). An open-label extension (560 mg Arikace) for 28 days followed by 56 days off over six cycles confirmed durable improvements in lung function and sputum P aeruginosa density (n=49).
Conclusions: Once-daily Arikace demonstrated acute tolerability, safety, biologic activity and efficacy in patients with CF with P aeruginosa infection.
Trial registration: ClinicalTrials.gov NCT00558844 NCT00777296.
Keywords: Bacterial Infection; Cystic Fibrosis; Respiratory Infection.
Figures
References
- Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science (New York, NY) 1989;245:1059–65
- Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science (New York, NY) 1989;245:1073–80
- Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992–2001
- Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med 2007;28:279–88
- Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581–8
- Dasenbrook EC, Merlo CA, Diener-West M, et al. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008;178:814–21
- Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010;303:2386–92
- Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23–30
- Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55–63
- McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921–8
- Oermann CM, Assael B, Nakamura C, et al. Poster: Aztreonam for Inhalation Solution (AZLI) vs. Tobramycin Inhalation Solution (TIS): a 6-month Comparative Trial in Cystic Fibrosis (CF) Patients with Pseudomonas aeruginosa (PA). Pediatr Pulmonol 2010;45(Supplement 33)(abs 305):327
- Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135:1223–32
- Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68:344–50
- Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45:1121–34
- Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011;10:54–61
- Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. J Cyst Fibros 2013;12:130–40
- Coates AL. Performance of PARI eFlow. J Aerosol Med Pulm Drug Deliv 2010;23:114; author reply -8
- Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61:859–68
- Li Z, Zhang Y, Wurtz W, et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008;21:245–54
- Clancy JP. Clinical Trials of Lipid-Associated Aerosolized Amikacin: the ArikaceTM Story. Pediatr Pulmonol 2009;44:109–212
- Weers J, Metzheiser B, Taylor G, et al. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 2009;22:131–8
- Chinoy MR, Fisher AB, Shuman H. Confocal imaging of time-dependent internalization and localization of NBD-PC in intact rat lungs. Am J Physiol 1994;266(6 Pt 1):L713–21
- Martini WZ, Chinkes DL, Barrow RE, et al. Lung surfactant kinetics in conscious pigs. Am J Physiol 1999;277(1 Pt 1):E187–95
- Babiker A, Andersson O, Lindblom D, et al. Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase: evidence that most of this steroid in the circulation is of pulmonary origin. J Lipid Res 1999;40:1417–25
- Diczfalusy U, Lund E, Lutjohann D, et al. Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols. Scand J Clin Lab Invest Suppl 1996;226:9–17
- Neville M, Liu S, Artis C, et al. Functionality of Foamy Alveolar Macrophages After Inhalation of Aerosolized Liposomal Amikacin (ArikaceTM). Pediatric Pulmonology 2009;44:109–212
Source: PubMed